GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

GSK is one of the top 20 largest companies in the U.K. with a current market capitalisation of over £55 billion. The ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

Under the agreement, GSK will pay $1billion upfront to acquire the Massachussetts-based firm, followed by up to $150million ...

THOUSANDS of holidaymakers face woes due to engine troubles on five British Airways jets. The airline axed flights from ...

GSK Plc's CEO Emma Walmsley has expressed intentions to engage in more business deals, as the British pharmaceutical company intensifies its focus on cancer treatments. This comes after GSK made ...

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio ...

FOR more than a century, the charming Sunbeams have been delighting audiences at Bradford’s Alhambra theatre. Introduced in 1917 as a “ray of sunshine”, the junior dance troupe took to the stage ...